anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adolescents with cerebral palsy (CP) have limitations to perform daily routine activities. The use of educational strategies associated to an approach based on motor learning principles was found to be effective in promoting motor outcomes in individuals with CP. However, there is a shortage of services focused on the specific needs of adolescents with CP and on the skills considered important for the success of the transition period to adulthood. Complementarily, the literature reveals the scarcity of services that provide educational support to parents on how to deal with the functional limitations of their adolescent children with CP. Therefore, it is possible that the development of an intervention protocol that associates high intensity training with specific functional goals with an educational program for parents and adolescents, can contribute to the provision of rehabilitation services targeted at adolescents with CP and their families. The overall objective of the present study is to investigate the effectiveness of an intensive, goal-directed protocol associated with education for parents and adolescents in promoting the daily functioning of adolescents with CP. A randomized clinical trial will be conducted with 20 adolescents with CP, aged between 12 and 17 years and 11 months, and their respective caregivers. Adolescents will be randomly allocated into one of two groups: (a) intensive training of functional goals with adolescents (3 hours/day, 5 days/week, during two weeks, totaling 30 hours, in a clinical setting) or (b) intensive functional goal training with adolescents, including parenting and adolescent education strategies (3 hours/day, 5 days/week, during two weeks, totaling 30 hours, with telehealth strategies and visits at the clinical setting).
Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject \< 60 minutes.
In the present randomized double-blind prospective study, the patients will be randomly assigned to the study and control groups. With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin and the control group will be given placebo. When endometrial thickness will be found between 8-14 mm, therapy with progesterone (100 mg IM daily) will be started and embryo transfer will be performed 48 to 72 hours later. Doppler ultrasonography also is done to calculate Resistive Index (RI) and Pulsatility Index (PI), the day after progesterone administration.

βHCG will be assessed 14 days after ET. If a pregnancy will be achieved, the patients in study and control groups will be instructed to continue the aspirin or placebo through 5 weeks and if the pregnancy test result will be negative, the treatment with aspirin or placebo will be stopped. The patients will be followed until 20 weeks of gestation and the results of treatment cycle will be compared in two groups.
Hodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patients in the six-cycle ABVD and BAPT groups respectively had similar survival curves for progression and death with a 49-month median follow-up. PFS rates were also very similar at two and four years from diagnosis with 2-year PFS rates of 83.9% and 82.1% (RR = 1.1 95%CI = 0.45-2.2). Outcome comparisons were also similar between the two groups when stratified according to early response assessment with PET/CT. Patients who discontinued bleomycin due to toxicity did not experience an increased risk of progression compared to patients who completed six ABVD cycles.
Background: Resident physicians are frequently uncomfortable ordering enteral nutrition (EN) and are unaware of the variety of formulas and supplements available for different disease processes. Many depend on a clinical dietitian to assist with recommending EN formulas and patient energy requirements which may not be readily available upon patient admission. This creates a barrier to early initiation of EN and non-compliance with Society of Critical Care Medicine and American Society of Parenteral and Enteral Nutrition clinical guidelines. Objective: Internal medicine resident physicians were provided an ipod with the EN application to assist them in choosing EN formulas for patients during their ICU rotation. The primary outcome was improved initiation of EN within 24 hours of admission. Secondary outcomes include, time to initiate EN, goal calories reached. Design: This study is a retrospective chart review to evaluate the impact of a smart phone/device application (EN application) to assist resident physicians when ordering EN. The study is a single center trial conducted at an academic teaching facility. All patient data was obtained by a retrospective chart review of patients admitted to the intensive care unit (ICU) at The University of Oklahoma Medical Center.
A cDNA clone encoding the human prohormone convertase PC5 was isolated from human adrenal gland messenger RNA. The deduced protein sequene would encode a 915 amino acid prepro PC5 which shares a very high degree of homology with the previously cloned rat and mouse homologues. PC5 mRNA is detected in multiple human tissues, including the brain, adrenal and thyroid glands, heart, placenta, lung and testes. PC5 mRNA was undetectable in the liver and is present at lower levels in skeletal muscle, kidney, pancreas, small intestine and stomach. Co-transfection of human PC5 and human prorenin expression vectors in cultured GH4Cl cells leads to secretion of active renin. The activation of human prorenin by PC5 is dependent on a pair of basic amino acids at positions 42 and 43 of the prorenin prosegment and occurs only in cells containing dense core secretory granules. Human PC5 was co-localized with renin by immunohistochemistry in the zona glomerulosa of the adrenal gland suggesting that it could participate in the activation of a local renin-angiotensin system in the human adrenal cortex. PC5 is overexpressed in atherosclerotic coronary blood vessels. Silencing PC5 expression with a specific antisense oligonucleotide efficiently inhibited the proliferation of smooth muscle cells in culture. Furthermore, the antisense inhibited carotid stenosis in a carotoid injury model. These results indicate that silencing PC5 applies to the prevention of restenosis. PCs could be targets of choice for treating any proliferative diseases involving their action on a given growth factor. Finally, the antisense oligonucleotide PC5 is to be used for silencing the activity of this enzyme towards HIV gp160, since both coexist in CD4+ T  lymphocytes and the viral glycoprotein is cleavable by PC5.
We investigated the impact of mesenchymal stem cell (MSC) therapy on treating bilateral human hip osteonecrosis, analyzing 908 cases. This study assesses factors such as tissue source and cell count, comparing core decompression with various cell therapies. This research emphasizes bone repair according to pre-treatment conditions and the specificities of cell therapy in osteonecrosis repair, indicating a potential for improved bone repair strategies in hips without femoral head collapse. This study utilized a single-center retrospective analysis to investigate the efficacy of cellular approaches in the bone repair of osteonecrosis. It examined the impact on bone repair of tissue source (autologous bone marrow concentrate, allogeneic expanded, autologous expanded), cell quantity (from none in core decompression alone to millions in cell therapy), and osteonecrosis stage and volume. Excluding hips with femoral head collapse, it focused on patients who had bilateral hip osteonecrosis, both pre-operative and post-operative MRIs, and a follow-up of over five years. The analysis divided these patients into seven groups based on match control treatment variations in bilateral hip osteonecrosis, primarily investigating the outcomes between core decompression, washing effect, and different tissue sources of MSCs. Younger patients (<30 years) demonstrated significantly better repair volumes, particularly in stage II lesions, than older counterparts. Additionally, bone repair volume increased with the number of implanted MSCs up to 1,000,000, beyond which no additional benefits were observed. No significant difference was observed in repair outcomes between different sources of MSCs (BMAC, allogenic, or expanded cells). The study also highlighted that a 'washing effect' was beneficial, particularly for larger-volume osteonecrosis when combined with core decompression. Partial bone repair was the more frequent event observed, while total bone repair of osteonecrosis was rare. The volume and stage of osteonecrosis, alongside the number of injected cells, significantly affected treatment outcomes. In summary, this study provides comprehensive insights into the effectiveness and variables influencing the use of mesenchymal stem cells in treating human hip osteonecrosis. It emphasizes the potential of cell therapy while acknowledging the complexity and variability of results based on factors such as age, cell count, and disease stage.
1299734 Preparing 3-Methyl-cephalosporanic acid esters GLAXO LABORATORIES Ltd 10 March 1970 [11 March 1969] 12865/69 Heading C2A 7# -Acylamido-3-methyl-cephalosporanic acid esters are prepared by heating a 6#-acylamidopenicillanic acid 1-oxide ester in a solvent selected from ketones boiling at 75‹ to 120‹ C., esters boiling at 75‹ to 140‹ C., dioxan (the heating being for at least 2 hours at 75‹ to 110‹C. and for at least 45 minutes at higher temperatures in these solvents), and diethylene glycol dimethyl ether, in the presence of a hydrocarbyl sulphonic acid or a phosphorus acid. Suitable ketones and esters are ethyl methyl ketone, isobutyl methyl ketone, methyl n-propyl ketone, n-propyl acetate, n-butyl acetate, iso-butyl acetate, sec-butyl acetate and diethyl carbonate. Hydrocarbyl sulphonic acids may be alkyl, aryl or aralkyl sulphonic acids. Phosphorus acids may be ortho-, poly- or pyrophosphoric acids, phosphonic or phosphorus acids; the phosphonic acids may be aliphatic, araliphatic or aryl and the organic moiety may be substituted e.g. by halogen or nitro. Typical such acids are methane-, ethane-, dichloromethane-, trichloromethane-, iodomethane-, bromobenzene- and nitrobenzenephosphonic acids. The acid is preferably used in a proportion of 0À05 to 0À2 mole and not exceeding 1À0 mole per mole of the penicillin oxide. The reaction is preferably carried out under reflux using a desiccant in the reflux return tube to remove water formed during the reaction. The product is isolated by removing the solvent e.g. by evaporation, and the acid, e.g. by water-washing if the solvent is water-immiscible or else by neutralizing with e.g. CaCO 3 or MgO and filtering, optionally decolorising the charcoal and precipitating the product with water, and crystallising or purifying by chromatography. The penicillin 1-oxide ester is obtained by esterifying the 3-carboxyl group and then oxidising the 1-sulphur group with an oxidising agent in an amount such that at least 1 atom of active oxygen per atom of thiazolidine sulphur is present. Typical oxidising agents are metaperiodic acid, peracetic acid, monoperphthalic acid, m-chloroperbenzoic acid, or t-butylhypochlorite with a weak base, e.g. pyridine. The penicillin 1-oxide ester preferably has protecting groups on any radicles present which are reactive in the various processes.
[GB1299734A]
SCOPE: Sensory neurons expressing the sodium channel Nav1.8 contain a repertoire of receptors for nutrient, hormonal, and inflammatory ligands. However, their function in key regulators of energy homeostasis control is not well understood and is completely unexplored in females.
METHODS AND RESULTS: Mice lacking neurons expressing the sodium channel Nav1.8 were generated using an ablation strategy based on cre recombinase-mediated expression of diphtheria toxin fragment A (DTA) (Nav1.8-cre/DTA mice) to investigate whether these neurons modulate body weight, food intake, gut hormone secretion, gastrointestinal transit, and glucose tolerance in response to nutrient challenges in a sex-dependent manner. Male Nav1.8-cre/DTA mice show resistance to gain weight in response to high-fat high-sugar diet (HFHSD), whereas females lacking Nav1.8+ neurons have improved oral glucose tolerance accompanied by higher insulin levels and attenuated glucagon secretion after an oral glucose load. Female Nav1.8-cre/DTA mice also show higher fasting and postprandial glucagon like peptide-1 (GLP-1) levels with an increased number of GLP-1-positive cells. Finally, ablation of Nav1.8-expressing neurons accelerates the gastrointestinal transit in female mice under HFHSD.
CONCLUSION: This data demonstrates sex-dependent differences in the Nav1.8-mediated regulation of energy metabolism, and provides new insights that may help in the design of sex-specific neuromodulation therapies for metabolic disorders induced by diets rich in fats and simple sugars.
A filter material for filtering leucocytes from a fraction of or whole human blood, comprises a shape-sustaining laid textile web having a thickness of between about 2 millimeters to about 12 millimeters and a bulk density of about 0.05 to 0.4 g/cm 3 . The web has a plurality of interlocked, staple, textile fibers with average deniers between about 0.05 and 0.75 and average lengths between about 3 millimeters and 15 millimeters. The textile fibers are substantially uniformly distributed in the web so as to form a matrix of the textile fibers with spaces between adjacent interstices of interlocked fibers. A plurality of fibrillated particles of a polymeric material, e.g. a textile fiber material, having a surface area of between 5 and 60 square meters per gram are substantially disposed within the spaces of the matrix. The fibrillated particles have a plurality of fine fibrils which are interlocked with adjacent textile fibers of the spaces such that the fibrillated particles are not substantially displaced from the web during filtration of the blood. The weight ratio of the fibrillated particles to the textile fibers is between about 1:99 and 40:60.
This project will take place in 7 sites across two settings: Inpatient (CAMH in Toronto, Douglas Hospital Research Centre in Montreal, Parkwood Institute in London, and the University of Calgary in Calgary); and LTCFs affiliated with CAMH in Toronto and Parkwood Institute in London.

After a project initiation phase of 6 months, the investigators will enroll and randomize 220 participants with AD-AA (110 inpatient and 110 in LTCFs) to ICP vs.TAU. In this randomized control trial (RCT) phase of the project, participants will be treated for 12 weeks. There will be two primary outcome measures: (i) the Cohen-Mansfield Agitation Inventory (CMAI) Total Frequency Score (CMAI-frequency) and (ii) the proportion of participants on polypharmacy. These measures will be conducted at baseline, end of non-pharmacological intervention phase, the mid-point of pharmacological interventions and end of RCT. Neuropsychiatric Inventory-Questionnaire (NPI-C) will be used to assess global burden of neuropsychiatric symptoms at baseline, end of non-pharmacological intervention phase and exit. The modified Clinical Global Impression of Change (CGIC) will also be measured at predetermined time points throughout the 12 weeks to determine response as defined by CGIC \< 3. CGIC is a 7-point Likert scale to rate each patient along a continuum from marked improvement to marked worsening, based on global clinical impression. Rating of \< 3 indicates moderate or marked improvement in agitation as compared to baseline. At the end of the RCT, each participant will be naturalistically followed up for an additional 6 months during which the investigators will collect both clinical and health economics data from the Institute for Clinical Evaluative Sciences (ICES) database. The RCT phase will be completed after 18 months, and during the last part of this project, the investigators will analyze the data from the RCT and complete all naturalistic follow-ups.
Cholestatic liver diseases (CLD) are characterized by impaired normal bile flow, culminating in excessive accumulation of toxic bile acids. The majority of patients with CLD ultimately progress to liver cirrhosis and hepatic failure, necessitating liver transplantation due to the lack of effective treatment. Recent investigations have underscored the pivotal role of the gut microbiota-bile acid axis in the progression of hepatic fibrosis via various pathways. The obstruction of bile drainage can induce gut microbiota dysbiosis and disrupt the intestinal mucosal barrier, leading to bacteria translocation. The microbial translocation activates the immune response and promotes liver fibrosis progression. The identification of therapeutic targets for modulating the gut microbiota-bile acid axis represents a promising strategy to ameliorate or perhaps reverse liver fibrosis in CLD. This review focuses on the mechanisms in the gut microbiota-bile acids axis in CLD and highlights potential therapeutic targets, aiming to lay a foundation for innovative treatment approaches.
To provide a granule usable as a turbidity-forming agent, and to obtain a bathing agent composition containing the granule.The granule contains not only titanium oxide and carboxymethylcellulose sodium but also a metal ion-sequestering agent and/or a disintegrator. The bathing agent composition contains the granule. The bathing agent composition having high preservation stability can be provided by using the granule. The bathing agent composition can be packaged in a paper container because of the high stability in the preservation, and has a large merit from the viewpoint of reduction of waste. Good solubility and dispersibility can be obtained even in an area where the hardness of tap water is high. (C)2004,JPO.
An improved method of making benefit agent delivery particles and improved microcapsules made by such method are disclosed. The method comprises the step of providing a first composition of aqueous phase 1, aqueous phase 2 and aqueous phase 3. Aqueous phase 1 comprises water and initiator; the aqueous phase 2 comprises water, a water-soluble or water-dispersible amine (meth) acrylate or hydroxy (meth) acrylate and a multifunctional (meth) acrylate. The aqueous phase 3 comprises water and carboxyalkyl (meth) acrylate and a base or quaternary ammonium acrylate. The first two aqueous phases are mixed to pre-react the hydroxy- (meth) acrylate or amine (meth) acrylate and the multifunctional (meth) acrylate to form a multifunctional hydroxy-amine (meth) acrylate prepolymer. Mixing the prepolymer with water phase 3; then emulsifying a second composition into the first composition by stirring under high shear; the second composition comprises an oil phase comprising an isocyanate and a benefit agent core material, thereby forming a wall surrounding the benefit agent core material.
PURPOSE:To provide the subject preparation little in change with time, containing tocopherol succinate, vitamin B1 and ascorbic acid with at least one of them coated with a coating agent. CONSTITUTION:The objective vitamin preparation containing, as active ingredients, (A) tocopherol succinate or a salt thereof, (B) a vitamin B1 or salt thereof, and (C) ascorbic acid or salt thereof, with at least one of the components coated with a coating agent (e.g. hydroxypropylmethyl cellulose). The contents of the components A, B and C in the final preparation are 0.1 l-80wt.%, 0.01-85wt.%, and 0.1-95wt.%, respectively. The amounts of the components B and C are 0.001-100 pts.wt. and 0.001-1000 pts.wt. per pt.wt. of the component A, respectively. The amount of the coating agent to be used is 0.1-300wt.% based on the component A, B, or C.
BACKGROUND: Chronic kidney disease (CKD) is a progressive systemic condition characterized by numerous complications. Among these, alterations in skeletal muscle physiology, such as sarcopenia, are particularly significant, as they are associated with poor outcomes and reduced quality of life.
SUMMARY: Various interventions, including pharmacological approaches and lifestyle modifications have been investigated to slow CKD progression and prevent or treat its complications. Physical exercise, in particular, has emerged as a promising intervention with multiple beneficial effects. These include improvements in physical functioning, increased muscle mass, modulation of metabolic abnormalities, and reduced cardiovascular risk. However, the pathophysiology of physical exercise in patients with kidney disease is complex and remains only partially understood. A crucial advancement in understanding this phenomenon has been the identification of myokines - molecules expressed and released by skeletal muscle in response to physical activity. These myokines can exert both paracrine and systemic effects, influencing not only skeletal muscle physiology but also other processes such as energy metabolism and lipid regulation.
KEY MESSAGES: The interplay among skeletal muscle, physical activity, and myokines may act as a pivotal regulator in various physiological processes, including aging, as well as in pathological conditions like cachexia and sarcopenia, frequently observed in CKD patients at different stages, including patients on dialysis. Despite the potential importance of this relationship, only a limited number of studies have explored the relationship between exercise and myokine, and the effect of this interaction on experimental models or individuals with kidney disease. In the following sections, we review and discuss this topic.
Alzheimer's disease (AD) is a degenerative disorder characterised by amyloid-beta aggregates activated by the accumulation of lipid molecules and their derivatives, especially 7-ketocholesterol (7KCh), an oxidised lipid that plays a great part in the progression of AD. The current therapeutics need bio-potential molecules and their biomedical application preventing 7KCh-induced cytotoxicity. In this study, bornyl acetate (BA) and menthol (ME), the natural monoterpenes were investigated for their neuroprotective effects against 7KCh-induced SH-SY5Y cells and their effects were compared to the standard drug galantamine (GA). 7KCh-induced changes like lipid accumulation, amyloid generation, free radical generation, acetylcholinesterase levels, calcium accumulation and mitochondrial membrane integrity were analysed in SH-SY5Y cells with or without BA and ME treatment. Furthermore, various mediators involved in the amyloidogenic, inflammatory and apoptotic pathways were studied. In our results, the cells induced with 7KCh upon co-treatment with BA and ME significantly reduced lipid accumulation and amyloid generation through toll-like receptor (TLR) 4 suppression and enhanced ATP binding cassette (ABCA) 1-mediated clearance. Co-treatment with BA and ME concurrently regulated oxidative stress, acetylcholinesterase activity, mitochondrial membrane potential and intracellular calcification altered by 7KCh-induced SH-SY5Y cells. Moreover, 7KCh-induced cells showed elevated mRNA levels of misfolded protein markers and apoptotic mediators which were significantly downregulated by BA and ME co-treatment. In addition, the protein expression of amyloidogenic, proinflammatory as well as pro-apoptotic markers was decreased by BA and ME co-treatment in 7KCh-induced cells. Overall, BA and ME mediated inhibition of amyloidogenic activation and cell survival against 7KCh-induced inflammation, thereby preventing the onset and progression of AD in comparison to GA.